BRPI0707044B8 - comprimido matricial insolúvel em água e processo de fabricação de comprimidos matriciais - Google Patents

comprimido matricial insolúvel em água e processo de fabricação de comprimidos matriciais

Info

Publication number
BRPI0707044B8
BRPI0707044B8 BRPI0707044A BRPI0707044A BRPI0707044B8 BR PI0707044 B8 BRPI0707044 B8 BR PI0707044B8 BR PI0707044 A BRPI0707044 A BR PI0707044A BR PI0707044 A BRPI0707044 A BR PI0707044A BR PI0707044 B8 BRPI0707044 B8 BR PI0707044B8
Authority
BR
Brazil
Prior art keywords
water
insoluble
matrix tablet
manufacturing process
matrix
Prior art date
Application number
BRPI0707044A
Other languages
English (en)
Inventor
Herry Catherine
Bacon Jonathan
Oury Pascal
Cailly - Dufestel Vincent
Original Assignee
Ethypharm Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37460138&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0707044(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ethypharm Sa filed Critical Ethypharm Sa
Publication of BRPI0707044A2 publication Critical patent/BRPI0707044A2/pt
Publication of BRPI0707044B1 publication Critical patent/BRPI0707044B1/pt
Publication of BRPI0707044B8 publication Critical patent/BRPI0707044B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

comprimido matricial insolúvel em água, processo de fabricação dos comprimidos matriciais e uso de uma composição farmacêutica na forma de comprimidos. comprimidos matriciais insolúveis em água capazes de liberar de modo prolongado ao longo do tempo princípios ativos suscetíveis de serem usados para fins de toxicomania, princípios ativos esses que estão dispersados em uma matriz de compressão constituída de pelo menos um excipiente escolhido no grupo que compreende os polímeros com liberação prolongada independentes de ph e insolúveis na água, os excipientes minerais e suas misturas e que apresentam uma resistência ao esmagamento de pelo menos 4 mpa.
BRPI0707044A 2006-03-01 2007-03-01 comprimido matricial insolúvel em água e processo de fabricação de comprimidos matriciais BRPI0707044B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0601842A FR2898056B1 (fr) 2006-03-01 2006-03-01 Comprimes resistant a l'ecrasement destines a eviter le detournement illicite
FR0601842 2006-03-01
PCT/EP2007/051967 WO2007099152A1 (fr) 2006-03-01 2007-03-01 Comprimés résistant à l'écrasement destinés à éviter le mésusage involontaire et le détournement illicite

Publications (3)

Publication Number Publication Date
BRPI0707044A2 BRPI0707044A2 (pt) 2011-04-12
BRPI0707044B1 BRPI0707044B1 (pt) 2021-03-02
BRPI0707044B8 true BRPI0707044B8 (pt) 2021-05-25

Family

ID=37460138

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0707044A BRPI0707044B8 (pt) 2006-03-01 2007-03-01 comprimido matricial insolúvel em água e processo de fabricação de comprimidos matriciais
BRPI0707043A BRPI0707043C8 (pt) 2006-03-01 2007-03-01 comprimidos matriciais insolúveis em água a base de oxicodona, seu processo de fabricação e uso de uma composição farmacêutica

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0707043A BRPI0707043C8 (pt) 2006-03-01 2007-03-01 comprimidos matriciais insolúveis em água a base de oxicodona, seu processo de fabricação e uso de uma composição farmacêutica

Country Status (17)

Country Link
US (3) US8501160B2 (pt)
EP (4) EP3115042A1 (pt)
JP (3) JP2009528329A (pt)
KR (2) KR101375903B1 (pt)
CN (3) CN102266302B (pt)
AU (2) AU2007220456B2 (pt)
BR (2) BRPI0707044B8 (pt)
CA (2) CA2643328C (pt)
EA (3) EA020550B1 (pt)
ES (3) ES2609469T3 (pt)
FR (1) FR2898056B1 (pt)
IL (2) IL193732A (pt)
MX (2) MX2008011240A (pt)
NZ (3) NZ571519A (pt)
SG (1) SG175666A1 (pt)
WO (2) WO2007099152A1 (pt)
ZA (2) ZA200807571B (pt)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
AU764453B2 (en) 1999-10-29 2003-08-21 Euro-Celtique S.A. Controlled release hydrocodone formulations
MXPA03003895A (es) 2000-10-30 2003-07-28 Euro Celtique Sa Formulaciones de hidrocodona de liberacion controlada.
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20040234602A1 (en) 2001-09-21 2004-11-25 Gina Fischer Polymer release system
EP1429744A1 (en) 2001-09-21 2004-06-23 Egalet A/S Morphine polymer release system
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
WO2004084868A1 (en) 2003-03-26 2004-10-07 Egalet A/S Morphine controlled release system
DE10361596A1 (de) * 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005005446A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE10336400A1 (de) * 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
NZ545202A (en) * 2003-08-06 2010-03-26 Gruenenthal Chemie Abuse-proofed dosage form comprising opiods and a high molecular weight polyethylene oxide
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102004020220A1 (de) * 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
DE102004032103A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
ZA200807571B (en) 2006-03-01 2009-08-26 Ethypharm Sa Crush-resistant tablets intended to prevent accidental misuse and unlawful diversion
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
DE102007011485A1 (de) * 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
AU2008286914B2 (en) 2007-08-13 2014-10-02 Ohemo Life Sciences Inc. Abuse resistant drugs, method of use and method of making
KR101616246B1 (ko) 2008-01-25 2016-05-02 그뤼넨탈 게엠베하 약제학적 투여형
AU2009243681B2 (en) * 2008-05-09 2013-12-19 Grunenthal Gmbh Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
CA2751667C (en) 2009-02-06 2016-12-13 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
FR2946533A1 (fr) 2009-06-12 2010-12-17 Ethypharm Sa Reduction des fluctuations plasmatiques d'opioides.
NZ597283A (en) 2009-06-24 2013-07-26 Egalet Ltd Controlled release formulations
TWI473628B (zh) * 2009-07-22 2015-02-21 用於對氧化敏感之類鴉片藥劑之抗破壞劑型
WO2011009602A1 (en) 2009-07-22 2011-01-27 Grünenthal GmbH Hot-melt extruded controlled release dosage form
FR2949062B1 (fr) * 2009-08-12 2011-09-02 Debregeas Et Associes Pharma Nouvelles formulations pharmaceutiques contre le mesusage des medicaments
FR2949061B1 (fr) 2009-08-12 2013-04-19 Debregeas Et Associes Pharma Microgranules flottants
EP3064064A1 (en) 2009-09-30 2016-09-07 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
US20110150989A1 (en) * 2009-12-22 2011-06-23 Mallinkckrodt Inc. Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
US9579285B2 (en) * 2010-02-03 2017-02-28 Gruenenthal Gmbh Preparation of a powdery pharmaceutical composition by means of an extruder
CN101843596B (zh) * 2010-03-26 2012-07-25 中国人民解放军广州疗养院 盐酸美沙酮分散片及其制备方法
CA2798702A1 (en) 2010-05-11 2011-11-17 Cima Labs Inc. Alcoholresistant metoprolol-containing extended-release oral dosage forms
WO2012028318A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising an anionic polymer
CA2808219C (en) * 2010-09-02 2019-05-14 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
ES2648129T3 (es) 2011-07-29 2017-12-28 Grünenthal GmbH Pastilla a prueba de manipulación que proporciona una liberación inmediata de un medicamento
AU2012289764B2 (en) 2011-07-29 2017-03-02 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
FR2983409B1 (fr) * 2011-12-06 2013-12-27 Ethypharm Sa Comprime susceptible de lutter contre le detournement par voie injectable
US20130225697A1 (en) 2012-02-28 2013-08-29 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
PL2838512T3 (pl) 2012-04-18 2018-12-31 Grünenthal GmbH Farmaceutyczna postać dawkowania odporna na niewłaściwe użycie i odporna na uderzeniowe uwalnianie dawki
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
AU2013285988A1 (en) 2012-07-06 2015-02-12 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
BR112015000320B1 (pt) 2012-07-12 2023-03-07 SpecGx LLC Composições farmacêuticas dissuasivas de abuso e seu processo de preparação
MX366159B (es) 2012-11-30 2019-07-01 Acura Pharmaceuticals Inc Liberacion autorregulada de ingrediente farmaceutico activo.
WO2014146093A2 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
JP6466417B2 (ja) 2013-05-29 2019-02-06 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 二峰性放出プロファイルを有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
AU2014273227B2 (en) 2013-05-29 2019-08-15 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
JP6449871B2 (ja) 2013-07-12 2019-01-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング エチレン−酢酸ビニルポリマーを含有する改変防止剤形
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9770514B2 (en) 2013-09-03 2017-09-26 ExxPharma Therapeutics LLC Tamper-resistant pharmaceutical dosage forms
WO2015065547A1 (en) 2013-10-31 2015-05-07 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
EP3073994A1 (en) 2013-11-26 2016-10-05 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of cryo-milling
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
AU2015237721B2 (en) 2014-03-26 2018-04-26 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release coated reservoir solid dosage form
EP3142646A1 (en) 2014-05-12 2017-03-22 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
EA201692388A1 (ru) 2014-05-26 2017-05-31 Грюненталь Гмбх Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
CA2910865C (en) 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose
CA2955229C (en) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
WO2016043698A1 (en) * 2014-09-15 2016-03-24 Inspirion Delivery Technologies, Llc Orally administrable compositions and methods of deterring abuse by intranasal administration
WO2016064873A1 (en) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
US20160256452A1 (en) * 2015-03-06 2016-09-08 Develco Pharma Schweiz Ag Composition Of Opioid Receptor Antagonists For Use In Treatment Of Constipation With Highly Increased Whole Gut Transit Time
BR112017021475A2 (pt) 2015-04-24 2018-07-10 Gruenenthal Gmbh forma de dosagem resistente à adulteração (tamper) com liberação imediata e resistência contra extração de solvente
WO2017040607A1 (en) 2015-08-31 2017-03-09 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
WO2017042325A1 (en) 2015-09-10 2017-03-16 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
WO2017151571A1 (en) * 2016-02-29 2017-09-08 First Time Us Generics Llc Abuse deterrent soft chewable drug formulations
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
CN107811985B (zh) * 2016-09-13 2021-05-28 四川科瑞德制药股份有限公司 一种抗癫痫缓释制剂及其制备方法与用途
US11324707B2 (en) 2019-05-07 2022-05-10 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US12589083B2 (en) 2019-05-07 2026-03-31 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
CN112451493B (zh) * 2020-12-04 2022-06-28 江苏恩华药业股份有限公司 一种防滥用的羟考酮口服缓释片及其制备方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773955A (en) 1970-08-03 1973-11-20 Bristol Myers Co Analgetic compositions
US3966940A (en) * 1973-11-09 1976-06-29 Bristol-Myers Company Analgetic compositions
GB8430346D0 (en) 1984-11-30 1985-01-09 Reckitt & Colmann Prod Ltd Analgesic compositions
US4874614A (en) * 1985-03-25 1989-10-17 Abbott Laboratories Pharmaceutical tableting method
DE3702029A1 (de) * 1987-01-24 1988-08-04 Basf Ag Waessriges oder pulverfoermiges, wasserdispergierbares praeparat eines in wasser schwerloeslichen pharmazeutischen wirkstoffs und verfahren zu seiner herstellung
GB8728294D0 (en) 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
DE9109852U1 (de) 1991-08-09 1991-12-12 CGS Gesellschaft für Entwicklung und Projektierung elektronischer Systeme mbH, 2000 Hamburg Vorrichtung zur Härteprüfung von Tabletten
WO1993012768A1 (en) * 1991-12-30 1993-07-08 Fmc Corporation Microcrystalline cellulose spheronization composition
US5656291A (en) * 1994-03-16 1997-08-12 Pharmacia & Upjohn Aktiebolag Controlled release preparation
US6413536B1 (en) * 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
JP4098376B2 (ja) 1996-09-05 2008-06-11 ビーエーエスエフ ソシエタス・ヨーロピア 錠剤特性の優れた水溶性ビタミン組成物およびその製造法
DE19709663A1 (de) * 1997-03-10 1998-09-17 Basf Ag Verwendung von redispergierbaren Polymerpulvern oder Polymergranulaten als Bindemittel zur Herstellung von festen pharmazeutischen Darreichungsformen
GB9802201D0 (en) 1998-02-03 1998-04-01 Cerestar Holding Bv Free-flowable directly compressible starch as binder,disintegrant and filler for compresion tablets and hard gelatine capsules
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6270790B1 (en) 1998-08-18 2001-08-07 Mxneil-Ppc, Inc. Soft, convex shaped chewable tablets having reduced friability
US20030118641A1 (en) 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
SG83757A1 (en) * 1999-12-09 2001-10-16 Wing Thye Lum Powder composition and method for polishing stone
EP2092936B1 (en) 2000-02-08 2013-03-20 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
DE10014588A1 (de) 2000-03-27 2001-10-04 Basf Ag Wirkstoffhaltige Schwimmformen enthaltend Polyvinylacetat und Polyvinylpyrrolidon, deren Verwendung und Herstellung
DE10015479A1 (de) * 2000-03-29 2001-10-11 Basf Ag Feste orale Darreichungsformen mit retardierter Wirkstofffreisetzung und hoher mechanischer Stabilität
KR100390522B1 (ko) * 2000-12-01 2003-07-07 피티플러스(주) 결정질 실리콘 활성층을 포함하는 박막트랜지스터 제조 방법
US6626848B2 (en) * 2001-03-30 2003-09-30 Eric M. Neuenfeldt Method and device to reduce needle insertion force
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
CA2446738C (en) * 2001-05-11 2012-05-29 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
US6708626B2 (en) * 2001-06-11 2004-03-23 Kobe Steel, Ltd. Double-walled damping structure
US7141250B2 (en) * 2001-08-06 2006-11-28 Euro-Celtique S.A. Pharmaceutical formulation containing bittering agent
US7332182B2 (en) * 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
US6592901B2 (en) 2001-10-15 2003-07-15 Hercules Incorporated Highly compressible ethylcellulose for tableting
DE102005005446A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032051A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE10361596A1 (de) * 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE10336400A1 (de) * 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
BRPI0506710A (pt) 2004-01-06 2007-05-02 Panacea Biotec Ltd composições farmacêuticas de liberação controlada
PT1765292T (pt) * 2004-06-12 2017-12-29 Collegium Pharmaceutical Inc Formulações de fármacos dissuasoras de abuso
CA2572491A1 (en) 2004-07-01 2006-01-12 Gruenenthal Gmbh Oral dosage form safeguarded against abuse
AT8586U1 (de) 2005-06-29 2006-10-15 Lannacher Heilmittel Orale retardformulierung sowie verfahren zu ihrer herstellung
ZA200807571B (en) 2006-03-01 2009-08-26 Ethypharm Sa Crush-resistant tablets intended to prevent accidental misuse and unlawful diversion

Also Published As

Publication number Publication date
HK1165263A1 (en) 2012-10-05
EA200870268A1 (ru) 2009-02-27
EA014652B1 (ru) 2010-12-30
BRPI0707044B1 (pt) 2021-03-02
EA020550B1 (ru) 2014-12-30
KR101375903B1 (ko) 2014-03-27
NZ571518A (en) 2011-11-25
EP1996166B1 (fr) 2016-10-05
ZA200807571B (en) 2009-08-26
US20090011016A1 (en) 2009-01-08
EP3115042A1 (fr) 2017-01-11
FR2898056B1 (fr) 2012-01-20
EA200870267A1 (ru) 2009-02-27
JP2009528329A (ja) 2009-08-06
CA2643330A1 (fr) 2007-09-07
IL193732A (en) 2016-05-31
WO2007099154A1 (fr) 2007-09-07
ES2609469T3 (es) 2017-04-20
EP2010157A1 (fr) 2009-01-07
JP5508722B2 (ja) 2014-06-04
CA2643328C (fr) 2014-12-09
ES2609695T5 (es) 2020-05-14
US20150246035A1 (en) 2015-09-03
JP5844312B2 (ja) 2016-01-13
AU2007220454A1 (en) 2007-09-07
JP2013231066A (ja) 2013-11-14
CN101394839A (zh) 2009-03-25
EP3115041A1 (fr) 2017-01-11
FR2898056A1 (fr) 2007-09-07
CA2643330C (fr) 2015-02-10
JP2009528328A (ja) 2009-08-06
CN101394840B (zh) 2016-01-13
BRPI0707043C8 (pt) 2021-05-25
SG175666A1 (en) 2011-11-28
EP2010157B2 (fr) 2019-09-18
CN102266302B (zh) 2014-07-09
EP3115041B1 (fr) 2023-10-25
BRPI0707044A2 (pt) 2011-04-12
AU2007220456B2 (en) 2012-06-14
EP2010157B1 (fr) 2016-10-05
CN102266302A (zh) 2011-12-07
BRPI0707043C1 (pt) 2021-05-11
BRPI0707043A2 (pt) 2011-04-12
EA015182B1 (ru) 2011-06-30
CA2643328A1 (fr) 2007-09-07
IL193732A0 (en) 2009-05-04
NZ571519A (en) 2012-06-29
AU2007220454B2 (en) 2012-06-14
WO2007099152A1 (fr) 2007-09-07
CN101394840A (zh) 2009-03-25
ES2609695T3 (es) 2017-04-21
ZA200807572B (en) 2009-08-26
NZ594935A (en) 2014-04-30
AU2007220456A1 (en) 2007-09-07
KR20080109007A (ko) 2008-12-16
BRPI0707043B1 (pt) 2021-01-26
US20100015223A1 (en) 2010-01-21
EA201170334A1 (ru) 2011-08-30
EP1996166A1 (fr) 2008-12-03
KR101445884B1 (ko) 2014-10-02
CN101394839B (zh) 2012-11-21
MX2008011240A (es) 2009-01-27
IL193733A0 (en) 2009-05-04
ES2965034T3 (es) 2024-04-10
MX2008011241A (es) 2009-01-27
IL193733A (en) 2014-11-30
US8501160B2 (en) 2013-08-06
KR20080110601A (ko) 2008-12-18

Similar Documents

Publication Publication Date Title
BRPI0707044B8 (pt) comprimido matricial insolúvel em água e processo de fabricação de comprimidos matriciais
CY1126116T1 (el) Φαρμακευτικες συνθεσεις αποτελουμενες απο νιλοτινιμπη
MX2008012731A (es) Tabletas de paracetamol de liberacion rapida.
PE20061449A1 (es) Composiciones farmaceuticas comprendiendo imatinib y un retardador de liberacion
CO5190672A1 (es) Composicion para la dosificacion oral, de disolucion instantanea
BRPI0606145B8 (pt) formas farmacêuticas sólidas de cloridrato de oxicodona resistentes ao rompimento com liberação sustentada
BRPI0513847A (pt) formulação de comprimido de liberação extendida contendo pramipexol ou um sal farmaceuticamente aceitável do mesmo, método para a fabricação do mesmo e uso do mesmo
TR201909267T4 (tr) Sinakalset HCl içeren hızlı çözünme formülasyonu.
CL2008001966A1 (es) Composicion de disolucion oral que comprende lamotrigina,en forma de particulas con lamotrigina recubiertas con una capa para enmascarar el sabor y granulos que comprenden un desinfectante y un alcohol de azucar y/o un hidrato de carbono; metodo de preparacion;uso para tratar trastornos del humor y prevencion de ataques.
ECSP077999A (es) Formulaciones de una sal de bupropion de liberación modificada
PA8578301A1 (es) Composicion de tabletas de liberacion sostenida de pramipexol
CR9704A (es) Composicion farmaceutica de liberacion modificada, proceso de preparacion y metodo para emplear la misma.
MX2009008952A (es) Microesferas que comprenden una matriz de sustancia activa resistente a jugo gastrico.
AR048033A1 (es) Composicion farmaceutica para moldear componentes que comprende copolimero de poli(met)acrilato, cubierta, conector o espaciador de capsula moldeado por inyeccion que tiene la composicion farmaceutica y forma de dosificacion farmaceutica de multicomponentes a partir de dicha composicion
AR055561A1 (es) Comprimidos con dispersion mejorada de la sustancia farmacologica
CR10668A (es) Comprimidos pediatricos de capecitabina
CL2008001678A1 (es) Forma de dosificación farmacéutica de liberacion prolongada en forma de comprimido, que consiste de nevirapina anhidra, hipromelosa, lactosa monohidrato y estearato de magnesio; y su procedimiento de preparación, util para el tratamiento de una infeccion por vih-1.
BRPI0418283A (pt) formulação de liberação prolongada e processo para a preparação de uma formulação de liberação prolongada
ATE352290T1 (de) Wärmeformbare feste pharmazeutische zusammensetzung für die kontrollierte freigabe von ivabradin
BRPI0821454B8 (pt) formulação farmacêutica, mistura de glicogênio, alginato e sais de metais alcalino terrosos, processos para a produção de um excipiente de liberação lenta, e de uma forma farmacêutica
MY139086A (en) Use of debranched starch in extrusion-spheronization pharmaceutical pellets
AR066000A1 (es) Procedimiento para preparar comprimidos de dihidrocloruro de pramipexol
DE602005013232D1 (de) Schnell zerfallende im mund dispergierbare zusammensetzung mit nicht-filamentösen mitverarbeiteten polyol-teilchen und verkieselter mikrokristalliner cellulose
BRPI0518789A2 (pt) formulaÇço farmacÊutica, processo para preparar uma formulaÇço farmacÊutica, produto, e, cÁpsula ou tablete
PE20160245A1 (es) Composicion farmaceutica anti-tuberculosis estable en una forma de un comprimido dispersable que comprende granulos de isoniazid y granulos de rifapentina y su proceso de preparacion

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/03/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/03/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF